FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR EVUSHELD™ (tixagevimab co-packaged with cilgavimab)

HIGHLIGHTS OF EMERGENCY USE AUTHORIZATION (EUA)
These highlights of the EUA do not include all the information needed to use EVUSHELD™ under the EUA. See the FULL FACT SHEET FOR HEALTHCARE PROVIDERS for EVUSHELD.

EVUSHELD (tixagevimab) injection. (cilgavimab) injection; co-packaged for intramuscular use
Original EUA Authorized Date: 12/2021

The U.S. Food and Drug Administration has issued an EUA for the emergency use of the unapproved product EVUSHELD (tixagevimab co-packaged with cilgavimab), SARS-CoV-2 spike protein-directed attachment inhibitor, for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and

- Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or

- For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

See Full Fact Sheet for Healthcare Providers for examples of medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination, the justification for emergency use of drugs during the COVID-19 pandemic, information on available alternatives, and additional information on COVID-19. (1)

DOSAGE AND ADMINISTRATION
The dosage of EVUSHELD for emergency use is 150 mg of tixagevimab and 150 mg of cilgavimab administered as two separate consecutive intramuscular injections. See Full Fact Sheet for Healthcare Providers for detail on preparation and administration. (2)

DOSAGE FORMS AND STRENGTHS
Injection:
- tixagevimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial. (3)
- cilgavimab 150 mg/1.5 mL (100 mg/mL) in a single-dose vial. (3)

CONTRAINDICATIONS
EVUSHELD is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of EVUSHELD. (4)

WARNINGS AND PRECAUTIONS

- Hypersensitivity Including Anaphylaxis: Serious hypersensitivity reactions, including anaphylaxis, have been observed with IgG1 monoclonal antibodies like EVUSHELD. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive therapy. Clinically monitor individuals after injections and observe...
EVUSHELD has been authorized by FDA for the emergency use described above. EVUSHELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. (1) EVUSHELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHELD under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

LIMITATIONS OF AUTHORIZED USE

• EVUSHELD is not authorized for use in individuals:
  ○ For treatment of COVID-19, or
  ○ For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.

• Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.

• In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.

for at least 1 hour. (5.1)

• Clinically Significant Bleeding Disorders: As with any other intramuscular injection, EVUSHELD should be given with caution to individuals with thrombocytopenia or any coagulation disorder. (5.2)

• Cardiovascular Events: A higher proportion of subjects who received EVUSHELD versus placebo reported myocardial infarction and cardiac failure serious adverse events. All of the subjects with events had cardiac risk factors and/or a prior history of cardiovascular disease, and there was no clear temporal pattern. A causal relationship between EVUSHELD and these events has not been established. Consider the risks and benefits prior to initiating EVUSHELD in individuals at high risk for cardiovascular events, and advise individuals to seek immediate medical attention if they experience any signs or symptoms suggestive of a cardiovascular event. (5.3)

----------ADVERSE REACTIONS-----

Most common adverse events (all grades, incidence ≥3%) are headache, fatigue, and cough. (6.1) You or your designee must report all SERIOUS ADVERSE EVENTS or MEDICATION ERRORS potentially related to EVUSHELD (1) by submitting FDA Form 3500 online, (2) by downloading this form and then submitting by mail or fax, or (3) contacting the FDA at 1-800-FDA-1088 to request this form. Please also provide a copy of this form to AstraZeneca by Fax at 1-866-742-7984 or call 1-800-236-9933. (6.4) See PATIENT AND PARENTS/CAREGIVER FACT SHEET.

TABLE OF CONTENTS*

1 EMERGENCY USE AUTHORIZATION
2 DOSAGE AND ADMINISTRATION
  2.1 Dosage for Emergency Use of EVUSHELD
  2.2 Dosage Adjustment in Specific
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
8.8 Other Specific Populations
10 OVERDOSAGE
1 EMERGENCY USE AUTHORIZATION

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product EVUSHIELD (tixagevimab co-packaged with cilgavimab) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals (12 years of age and older weighing at least 40 kg):

- Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and

  - Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination or
  - For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g., severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

EVUSHIELD has been authorized by FDA for the emergency use described above. EVUSHIELD is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19.

EVUSHIELD is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of EVUSHIELD under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:
Justification for Emergency Use of Drugs During the COVID-19 Pandemic

There is currently an outbreak of COVID-19 caused by SARS-CoV-2, a novel coronavirus. The Secretary of HHS has declared that:

- Circumstances exist justifying the authorization of emergency use of drugs and biological products during the COVID-19 pandemic (March 27, 2020 declaration).

An EUA is a FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include:

- The biological agent(s) can cause a serious or life-threatening disease or condition;
- Based on the totality of the available scientific evidence (including data from adequate and well-controlled clinical trials, if available), it is reasonable to believe that:
  - The product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and
  - The known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential

LIMITATIONS OF AUTHORIZED USE

- EVUSHELD is not authorized for use in individuals:
  - For treatment of COVID-19, or
  - For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.

- Pre-exposure prophylaxis with EVUSHELD is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate to severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID-19 vaccination.

- In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination.
Information Regarding Available Alternatives for the EUA Authorized Use

There are no adequate, approved and available alternatives to EVUSHELD for the pre-exposure prophylaxis of COVID-19 in individuals who may not mount an adequate immune response to COVID-19 vaccination or for whom COVID-19 vaccination is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine or its components.

For information on clinical studies of EVUSHELD and other therapies for the prophylaxis of COVID-19, see www.clinicaltrials.gov.

1 For additional information please see https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html. Healthcare providers should consider the benefit-risk for an individual patient.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage for Emergency Use of EVUSHELD

The dosage of EVUSHELD in adults and pediatric individuals (12 years of age and older weighing at least 40 kg) is 150 mg of tixagevimab and 150 mg of cilgavimab administered as two separate consecutive intramuscular (IM) injections.

Repeat Dosing

Longer term data from the study PROVENT indicate that EVUSHELD may be effective for pre-exposure prophylaxis for 6 months post-administration [see Clinical Studies (14)]. While SARS-CoV-2 remains in circulation, individuals who qualify for EVUSHELD, per the conditions of the EUA, can be redosed every 6 months.

EVUSHELD has only been studied in single-dose studies. There are no safety and efficacy data available with repeat dosing. The recommendation for repeat dosing is based on the totality of the scientific evidence including clinical pharmacology data and clinical trial data [see Clinical Pharmacology (12.3) and Clinical Studies (14)].

2.2 Dosage Adjustment in Specific Populations

No dosage adjustment is recommended in pregnant or lactating individuals, in geriatrics, and in individuals with renal impairment [see Use in Specific Populations (8)].

2.3 Dose Preparation and Administration

Each EVUSHELD carton contains two vials; one of each antibody. Each vial contains an overfill to allow the withdrawal of 150 mg (1.5 mL).

<table>
<thead>
<tr>
<th>Table 1 Dosage of Tixagevimab and Cilgavimab</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EVUSHELD</strong> (tixagevimab co-packaged cilgavimab)</td>
</tr>
<tr>
<td>------</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
3 DOSAGE FORMS AND STRENGTHS

EVUSHELD is available as an individual single-dose vial of tixagevimab as a clear to opalescent, colorless to slightly yellow solution co-packaged with an individual single-dose vial of cilgavimab as a clear to opalescent, colorless to slightly yellow solution as:

<table>
<thead>
<tr>
<th>cilgavimab</th>
<th>1 vial cap</th>
<th>1.5 mL</th>
</tr>
</thead>
<tbody>
<tr>
<td>150 mg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* 150 mg of tixagevimab and 150 mg of cilgavimab are to be administered as separate, consecutive intramuscular injections

Preparation

- Tixagevimab and cilgavimab must be prepared by a qualified healthcare provider.
- Tixagevimab and cilgavimab are each supplied in individual single-dose vials. Do not shake the vials.
- Visually inspect the vials for particulate matter and discoloration. Tixagevimab and cilgavimab are clear to opalescent, colorless to slightly yellow solutions. Discard the vials if the solution is cloudy, discolored or visible particles are observed.
- Withdraw 1.5 mL of tixagevimab solution and 1.5 mL of cilgavimab solution into TWO separate syringes (see Table 1). Discard unused portion in vials.
- This product is preservative-free and therefore, the prepared syringes should be administered immediately. If immediate administration is not possible, and the prepared tixagevimab and cilgavimab syringes need to be stored, the total time from vial puncture to administration must not exceed 4 hours:
  - in a refrigerator at 2°C to 8°C (36°F to 46°F), or
  - at room temperature up to 25°C (77°F).

Administration

- Tixagevimab and cilgavimab must be administered by a qualified healthcare provider.
- Administer the two components of EVUSHELD consecutively.
- Administer the IM injections at different injection sites, preferably one in each of the gluteal muscles, one after the other.
- Clinically monitor individuals after injections and observe for at least 1 hour [see Warnings and Precautions (5.1)].

4 CONTRAINDICATIONS

EVUSHELD is contraindicated in individuals with previous severe hypersensitivity reactions, including anaphylaxis, to any component of EVUSHELD [see Warnings and Precautions (5.1)].

5 WARNINGS AND PRECAUTIONS

There are limited clinical data available for EVUSHELD. Serious and unexpected adverse events may occur that have not been previously reported with EVUSHELD use.

5.1 Hypersensitivity Including Anaphylaxis
Serious hypersensitivity reactions, including anaphylaxis, have been observed with Human immunoglobulin G1 (IgG1) monoclonal antibodies like EVUSHELD [see Adverse Reactions (6.1)]. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur while taking EVUSHELD, immediately discontinue administration and initiate appropriate medications and/or supportive care. Clinically monitor individuals after injections and observe for at least 1 hour.

5.2 Clinically Significant Bleeding Disorders
As with any other intramuscular injection, EVUSHELD should be given with caution to individuals with thrombocytopenia or any coagulation disorder.

5.3 Cardiovascular Events
In PROVENT there was a higher rate of cardiovascular serious adverse events (SAEs), including myocardial infarction (one fatal SAE) and cardiac failure, in subjects who received EVUSHELD compared to placebo [see Adverse Reactions (6.1)]. All subjects who experienced cardiac SAEs had cardiac risk factors and/or a prior history of cardiovascular disease, and there was no clear temporal pattern. A causal relationship between EVUSHELD and these events has not been established. There was no signal for cardiac toxicity or thrombotic events identified in the nonclinical studies.

Consider the risks and benefits prior to initiating EVUSHELD in individuals at high risk for cardiovascular events, and advise individuals to seek immediate medical attention if they experience any signs or symptoms suggestive of a cardiovascular event.

6 ADVERSE REACTIONS

6.1 Adverse Reactions from Clinical Studies
The following adverse events have been observed in the clinical studies of EVUSHELD that supported the EUA. The adverse event rates observed in these clinical studies cannot be directly compared to rates in the clinical studies of other products and may not reflect the rates observed in clinical practice. Additional adverse events associated with EVUSHELD may become apparent with more widespread use.

Approximately 4,220 subjects have been exposed to EVUSHELD (tixagevimab 150 mg and cilgavimab 150 mg) in clinical trials.

The safety of EVUSHELD is based on analyses from two ongoing Phase III trials, PROVENT and STORM CHASER. In both studies, adults received EVUSHELD (150 mg of tixagevimab and 150 mg of cilgavimab) administered as two separate consecutive IM injections or placebo [see Clinical Studies (14)].

The primary safety analysis was based on data through to an event driven efficacy data cut-off, such that individual subjects had variable follow-up times [see Clinical Studies (14)], with a median (range) of follow-up of 83 days (3-166 days) for PROVENT and 49 days (5-115 days) for STORM CHASER. An additional data cut-off was conducted to provide updated analyses with a median (range) of follow-up of 6.5 months (3-282 days) for PROVENT and approximately 6 months (5-249 days) for STORM CHASER. The median and range of follow-up times were similar between EVUSHELD and placebo recipients in each trial.

PROVENT
PROVENT enrolled adults ≥18 years of age who were either ≥60 years of age, had pre-specified co-morbidities [see Clinical Studies (14)], or were at increased risk of SARS-CoV-2 infection due to their living situation or occupation. Subjects could not have previously received a COVID-19 vaccine or have known prior or current SARS-CoV-2
infection. Subjects received a single dose of EVUSHELD (N= 3,461) or placebo (N= 1,736).

Adverse events were reported in 1,221 (35%) subjects receiving EVUSHELD and 593 (34%) receiving placebo. SAEs were reported in 50 (1%) subjects receiving EVUSHELD and 23 (1%) receiving placebo. There was 1 adverse event reported as anaphylaxis among subjects who received EVUSHELD. The event began within minutes of EVUSHELD administration and was treated with epinephrine. The event resolved.

Of the reported adverse events (N= 4,507), the majority were mild (73%) or moderate (24%) in severity. All adverse events, occurring in at least 1% of subjects, were reported at similar incidence rates among subjects receiving EVUSHELD compared to those receiving placebo (difference <1%). The most common treatment-emergent adverse events, occurring in at least 3% of subjects receiving EVUSHELD or placebo are shown in Table 2.

### Table 2 Adverse Events (All Grades) Regardless of Causality Occurring in at Least 3% of Subjects Receiving EVUSHELD or Placebo in Primary Safety Analysis

<table>
<thead>
<tr>
<th></th>
<th>EVUSHELD N= 3,461</th>
<th>Placebo N= 1,736</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>6%</td>
<td>5%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>4%</td>
<td>3%</td>
</tr>
<tr>
<td>Cough</td>
<td>3%</td>
<td>3%</td>
</tr>
</tbody>
</table>

At the additional data cut-off (median follow-up 6.5 months), the overall adverse event profile for subjects who received EVUSHELD remained similar to events displayed in Table 2.

**Cardiac Serious Adverse Events**

Through the additional data cut-off in PROVENT, a higher proportion of subjects who received EVUSHELD versus placebo in PROVENT reported myocardial infarction SAEs, one of which resulted in death, and cardiac failure SAEs (see Table 3 below). All subjects who experienced cardiac SAEs had cardiac risk factors and/or a prior history of cardiovascular disease at baseline. There was no clear temporal pattern, with events reported from several hours after EVUSHELD receipt through the end of the follow-up period.

### Table 3 Cardiac SAEs Regardless of Causality in PROVENT with Onset Prior to Day 183 Using the Median 6-Month Data Cut-off Date

<table>
<thead>
<tr>
<th></th>
<th>EVUSHELD N= 3,461</th>
<th>Placebo N= 1,736</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subjects with any cardiac SAE*</td>
<td>22 (0.6%)</td>
<td>3 (0.2%)</td>
</tr>
<tr>
<td>SAEs related to coronary artery disease or myocardial ischemia†</td>
<td>10 (0.3%)</td>
<td>2 (0.1%)</td>
</tr>
<tr>
<td>Myocardial infarctions‡</td>
<td>8 (0.2%)</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td>SAEs related to cardiac failure§α</td>
<td>6 (0.2%)</td>
<td>1 (0.1%)</td>
</tr>
<tr>
<td></td>
<td>4 (0.1%)</td>
<td>1 (0.1%)</td>
</tr>
</tbody>
</table>
STORM CHASER

STORM CHASER enrolled adults ≥18 years of age following potential exposure (within 8 days) to an identified individual with a laboratory-confirmed SARS-CoV-2 infection (symptomatic or asymptomatic). Subjects could not have previously received a COVID-19 vaccine, have symptoms consistent with COVID-19, or have a known prior SARS-CoV-2 infection. Subjects received a single dose of EVUSHELD (N= 749) or placebo (N= 372).

Adverse events were reported in 162 (22%) subjects receiving EVUSHELD and 111 (30%) receiving placebo. SAEs were reported in 5 (<1%) subjects receiving EVUSHELD and 3 (<1%) receiving placebo. Of the reported adverse events (N= 777), the majority were mild (75%) or moderate (23%) in severity.

At the additional data cut-off (median follow-up approximately 6 months), the overall adverse event profile for subjects who received EVUSHELD remained similar to earlier results. EVUSHELD is not authorized for post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2 [see Emergency Use Authorization (1)].

Cardiac Serious Adverse Events

In STORM CHASER (N= 1,121) no cardiac SAEs were reported (median follow-up approximately 6 months). Compared to PROVENT, the subjects in STORM CHASER were younger (median age 48 versus 57 years) and had fewer baseline cardiac risk factors (24% versus 36% with hypertension, 11% versus 14% with diabetes, and 3% versus 8% with cardiovascular disease in STORM CHASER versus PROVENT, respectively).

6.4 Required Reporting for Serious Adverse Events and Medication Errors

The prescribing healthcare provider and/or the provider’s designee is/are responsible for mandatory reporting of all serious adverse events* and medication errors potentially related to EVUSHELD within 7 calendar days from the healthcare provider’s awareness of the event, using FDA Form 3500 (for information on how to access this form, see below). The FDA recommends that such reports, using FDA Form 3500, include the following:

- Patient demographics and baseline characteristics (e.g., patient identifier, age or date of birth, gender, weight, ethnicity, and race)
- A statement “EVUSHELD use for COVID-19 under Emergency Use Authorization (EUA)” under the “Describe Event, Problem, or Product Use/Medication Error” heading
- Information about the serious adverse event or medication error (e.g., signs and symptoms, test/laboratory data, complications, timing of drug initiation in relation to
Submit adverse event and medication error reports, using Form 3500, to FDA MedWatch using one of the following methods:

- Complete and submit the report online: [www.fda.gov/medwatch/report.htm](http://www.fda.gov/medwatch/report.htm)
- Complete and submit a postage-paid FDA Form 3500 ([https://www.fda.gov/media/76299/download](https://www.fda.gov/media/76299/download)) and return by:
  - Mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787, or
  - Fax to 1-800-FDA-0178, or
- Call 1-800-FDA-1088 to request a reporting form

In addition, please provide a copy of all FDA MedWatch forms to AstraZeneca:

- Fax 1-866-742-7984

and to report adverse events please:

- Visit [https://contactazmedical.astrazeneca.com](https://contactazmedical.astrazeneca.com), or
- Call AstraZeneca at 1-800-236-9933.

The prescribing health care provider and/or the provider’s designee is/are to provide mandatory responses to requests from FDA for information about adverse events and medication errors associated with EVUSHELD.

*Serious adverse events are defined as:

- Death or a life-threatening adverse event;
- A medical or surgical intervention to prevent death, a life-threatening event, hospitalization, disability, or congenital anomaly;
- Inpatient hospitalization or prolongation of existing hospitalization;
- A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; or
- A congenital anomaly/birth defect.

### 7 DRUG INTERACTIONS

Drug-drug interaction studies have not been performed.

Tixagevimab and cilgavimab are not renally excreted or metabolized by cytochrome P450 (CYP) enzymes; therefore, interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of CYP enzymes are unlikely [see Clinical Pharmacology (12.3)].

### 8 USE IN SPECIFIC POPULATIONS

#### 8.1 Pregnancy

**Risk Summary**

There are insufficient data to evaluate a drug-associated risk of major birth defects,
miscarriage, or adverse maternal or fetal outcomes. EVUSHELD should only be used during pregnancy if the potential benefit outweighs the potential risk for the mother and the fetus.

Nonclinical reproductive toxicity studies have not been conducted with tixagevimab and cilgavimab. In a tissue cross-reactivity study assessing off-target binding of tixagevimab and cilgavimab to human fetal tissues no binding of clinical concern was observed. Human immunoglobulin G1 (IgG1) antibodies are known to cross the placental barrier; therefore, tixagevimab and cilgavimab have the potential to be transferred from the mother to the developing fetus. It is unknown whether the potential transfer of tixagevimab and cilgavimab provides any treatment benefit or risk to the developing fetus.

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

8.2 Lactation

Risk Summary

There are no available data on the presence of tixagevimab or cilgavimab in human milk or animal milk, the effects on the breastfed infant, or the effects of the drug on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for EVUSHELD and any potential adverse effects on the breastfed infant from EVUSHELD.

8.4 Pediatric Use

EVUSHELD is not authorized for use in pediatric individuals under 12 years of age or weighing less than 40 kg. The safety and effectiveness of EVUSHELD have not been established in pediatric individuals. The dosing regimen is expected to result in comparable serum exposures of tixagevimab and cilgavimab in individuals 12 years of age and older and weighing at least 40 kg as observed in adults, since adults with similar body weight have been included in the trials PROVENT and STORM CHASER [see Adverse Reactions (6.1) and Clinical Studies (14)].

8.5 Geriatric Use

Of the 2,029 subjects in the pooled pharmacokinetics (PK) analysis (Phase I and Phase III studies), 23% (N= 461) were 65 years of age or older and 3.3% (N= 67) were 75 years of age or older. There is no clinically meaningful difference in the PK of tixagevimab and cilgavimab in geriatric subjects (≥65 years) compared to younger subjects.

8.6 Renal Impairment

Tixagevimab and cilgavimab are not eliminated intact in the urine, renal impairment is not expected to affect the exposure of tixagevimab and cilgavimab. Similarly, dialysis is not expected to impact the PK of tixagevimab and cilgavimab.

8.7 Hepatic Impairment

The effect of hepatic impairment on the PK of tixagevimab and cilgavimab is unknown.

8.8 Other Specific Populations

Based on a population PK analysis, the PK profile of tixagevimab and cilgavimab was not
affected by sex, age, race, or ethnicity. Population PK model-based simulations suggest that body weight had no clinically relevant effect on the PK of tixagevimab and cilgavimab in healthy adults over the range of 36 kg to 177 kg.

10 OVERDOSAGE

Treatment of overdose with EVUSHELD should consist of general supportive measures including the monitoring of the clinical status of the individual. There is no specific treatment for overdose with EVUSHELD.

11 DESCRIPTION

Tixagevimab, a SARS-CoV-2 spike protein-directed attachment inhibitor, is a human immunoglobulin G1 (IgG1κ) monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. The molecular weight is approximately 149 kDa.

Tixagevimab injection is a sterile, preservative-free, clear to opalescent and colorless to slightly yellow solution supplied in a single-dose vial for intramuscular use. The vial stoppers are not made with natural rubber latex. Each 1.5 mL contains 150 mg tixagevimab, L- histidine (2.4 mg), L- histidine hydrochloride monohydrate (3.0 mg), polysorbate 80 (0.6 mg), sucrose (123.2 mg), and Water for Injection, USP. The pH is 6.0.

Cilgavimab, a SARS-CoV-2 spike protein-directed attachment inhibitor, is a human IgG1κ monoclonal antibody produced in CHO cells by recombinant DNA technology. The molecular weight is approximately 152 kDa.

Cilgavimab injection is a sterile, preservative-free, clear to opalescent and colorless to slightly yellow solution supplied in a single-dose vial for intramuscular use. The vial stoppers are not made with natural rubber latex. Each 1.5 mL contains 150 mg cilgavimab, L- histidine (2.4 mg), L- histidine hydrochloride monohydrate (3.0 mg), polysorbate 80 (0.6 mg), sucrose (123.2 mg), and Water for Injection, USP. The pH is 6.0.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Tixagevimab and cilgavimab are two recombinant human IgG1κ monoclonal antibodies with amino acid substitutions to extend antibody half-life (YTE), reduce antibody effector function, and minimize the potential risk of antibody-dependent enhancement of disease (TE). Tixagevimab and cilgavimab can simultaneously bind to non-overlapping regions of the receptor binding domain (RBD) of SARS-CoV-2 spike protein. Tixagevimab, cilgavimab, and their combination bind to spike protein with equilibrium dissociation constants of $K_D = 2.76 \text{ pM}$, $13.0 \text{ pM}$ and $13.7 \text{ pM}$, respectively, blocking its interaction with human ACE2, the SARS-CoV-2 receptor, which is required for virus attachment. Tixagevimab, cilgavimab, and their combination blocked RBD binding to human ACE2 with IC$_{50}$ values of 0.32 nM (48 ng/mL), 0.53 nM (80 ng/mL), and 0.43 nM (65 ng/mL), respectively.

12.3 Pharmacokinetics

A summary of PK parameters and properties of tixagevimab and cilgavimab following administration of a single EVUSHELD (150 mg of tixagevimab and 150 mg of cilgavimab) intramuscular dose is provided in Table 4.
Table 4 Summary of PK Parameters and Properties of Tixagevimab and Cilgavimab Following a Single EVUSHELD Intramuscular Dose

<table>
<thead>
<tr>
<th>PK Parameters</th>
<th>Tixagevimab</th>
<th>Cilgavimab</th>
</tr>
</thead>
<tbody>
<tr>
<td>$C_{\text{max}}$ ($\mu g/mL$)*</td>
<td>16.5 (35.6)</td>
<td>15.3 (38.5)</td>
</tr>
<tr>
<td>$T_{\text{max}}$ (day)$†$</td>
<td>14.0 (3.1 - 30)</td>
<td>14.0 (3.1 - 60)</td>
</tr>
<tr>
<td>$C_1$ ($\mu g/mL$)$‡$</td>
<td>4.4 (92.2)</td>
<td>3.9 (94.4)</td>
</tr>
<tr>
<td>$C_{150}$ ($\mu g/mL$)$§$</td>
<td>6.6 (25.6)</td>
<td>5.5 (35.2)</td>
</tr>
<tr>
<td>$C_{210}$ ($\mu g/mL$)$¶$</td>
<td>4.0 (31.6)</td>
<td>3.9 (37.1)</td>
</tr>
<tr>
<td>AUC$_{\text{inf}}$ (day $\cdot \mu g/mL$)</td>
<td>2529 (30.2)</td>
<td>2133 (31.7)</td>
</tr>
</tbody>
</table>

**Absorption**

<table>
<thead>
<tr>
<th> </th>
<th> </th>
<th> </th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioavailability$#$</td>
<td>68.5</td>
<td>65.8</td>
</tr>
</tbody>
</table>

**Distribution**

|$C_{\text{max}}$ ($\mu g/mL$) | 7.7 (1.97) | 8.7 (2.73) |

**Elimination**

<table>
<thead>
<tr>
<th> </th>
<th> </th>
<th> </th>
</tr>
</thead>
<tbody>
<tr>
<td>Half-life (days)$#$</td>
<td>87.9 (13.9)</td>
<td>82.9 (12.3)</td>
</tr>
</tbody>
</table>

**Metabolism**

Catabolic pathways; Same manner as endogenous IgG

**Excretion**

Not likely to undergo renal excretion

* Geomean (geometric %CV)  
† Median (range)  
‡ Observed geomean (geometric %CV) concentration 1 day after dosing  
§ Observed geomean (geometric %CV) concentration 150 days after dosing  
¶ Observed geomean (geometric %CV) concentration 210 days after dosing  
# Arithmetic mean (SD)

For repeat dose pre-exposure prophylaxis, it is expected that 6-month repeat EVUSHELD dosing will result in steady-state serum tixagevimab and cilgavimab trough concentrations greater than or equal to Day 183 tixagevimab and cilgavimab serum concentrations following a single EVUSHELD dose. Predicted steady-state serum tixagevimab and cilgavimab trough concentrations after 6-month repeat EVUSHELD dosing are in the range of the observed mean Day 150 and mean Day 210 concentration in serum (Table 4) following a single EVUSHELD dose.

**Specific Populations**
The PK profile of tixagevimab and cilgavimab were not affected by sex, age, race or ethnicity. Body weight had no clinically relevant effect on the PK of tixagevimab and cilgavimab in adults over the range of 36 kg to 177 kg.

**Pediatric Population**

The PK of tixagevimab and cilgavimab in pediatric individuals have not been evaluated. The dosing regimen is expected to result in comparable plasma exposures of tixagevimab and cilgavimab in pediatric individuals ages 12 years of age or older who weigh at least 40 kg as observed in adult individuals [see Use in Specific Populations (8.4)].

**Renal impairment**

Tixagevimab and cilgavimab are not eliminated intact in the urine. Renal impairment is not expected to impact the PK of tixagevimab and cilgavimab, since monoclonal antibodies with molecular weight >69 kDa are known not to undergo renal elimination. Similarly, dialysis is not expected to impact the PK of tixagevimab and cilgavimab.

There is no difference in the clearance of tixagevimab and cilgavimab in individuals with mild or moderate renal impairment compared to individuals with normal renal function. There were insufficient subjects with severe renal impairment to draw conclusions [see Use in Specific Populations (8.6)].

**Hepatic impairment**

No specific studies have been conducted to examine the effects of hepatic impairment on the PK of tixagevimab and cilgavimab. The impact of hepatic impairment on the PK of tixagevimab and cilgavimab is unknown [see Use in Specific Populations (8.7)].

**Drug Interaction Studies**

Drug-drug interaction studies have not been performed. Based on key elimination pathways, tixagevimab and cilgavimab interactions with concomitant medications that are renally excreted or that are substrates, inducers, or inhibitors of CYP enzymes are unlikely [see Drug Interactions (7)].

**12.4 Microbiology**

**Antiviral Activity**

In a neutralization assay on Vero E6 cells, tixagevimab, cilgavimab, and their combination neutralized SARS-CoV-2 (USA-WA1/2020 isolate) with EC50 values of 60.7 pM (9 ng/mL), 211.5 pM (32 ng/mL), and 65.9 pM (10 ng/mL), respectively.

Tixagevimab, cilgavimab, and their combination showed reduced or no antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), or antibody-dependent natural killer cell activation (ADNKA) in cell culture studies. Tixagevimab, cilgavimab, and their combination did not mediate antibody-dependent complement deposition (ADCD) activity with guinea pig complement proteins.

**Antibody Dependent Enhancement (ADE) of Infection**

The potential of tixagevimab and cilgavimab to mediate antibody-dependent viral entry was assessed in FcγRII-expressing Raji cells co-incubated with recombinant virus-like particles (VLPs) pseudotyped with SARS-CoV-2 spike protein, with antibody concentrations at a range of 6.6 nM (1 µg/mL) to 824 pM (125 ng/mL). Tixagevimab, cilgavimab, and their combination did not mediate entry of VLPs into these cells under the tested conditions.

The potential for ADE was also evaluated in a non-human primate model of SARS-CoV-2
using EVUSHELD. Intravascular administration prior to virus inoculation resulted in a dose-dependent improvement in all measured outcomes (total viral RNA in the lungs or nasal mucosae, infectious virus levels in the lungs based on TCID50 measurements, or lung injury and pathology based on histology measurements). No evidence of enhancement of viral replication or disease was observed at any dose evaluated, including sub-neutralizing doses down to 0.04 mg/kg.

Antiviral Resistance

There is a potential risk of treatment failure due to the development of viral variants that are resistant to tixagevimab and cilgavimab. Prescribing healthcare providers should consider the prevalence of SARS-CoV-2 variants in their area, where data are available, when considering prophylactic treatment options.

Escape variants were identified following serial passage in cell culture of SARS-CoV-2 or replication competent recombinant vesicular stomatitis virus (VSV) expressing SARS-CoV-2 spike protein in the presence of tixagevimab or cilgavimab individually or in combination. Variants which showed reduced susceptibility to tixagevimab expressed spike protein amino acid substitutions R346I (>200-fold), K444E (>200-fold), and K444R (>200-fold). No escape variants to tixagevimab, or the tixagevimab and cilgavimab combination were selected.

In neutralization assays using recombinant VLPs pseudotyped with SARS-CoV-2 spike and harboring individual spike amino acid substitutions identified in circulating SARS-CoV-2, variants with reduced susceptibility to cilgavimab alone included those with R346I (>200-fold), K444E (>200-fold), K444Q (>200-fold), K444R (>200-fold), V445A (21- to 51-fold), G446V (4.2-fold), N450K (9.1-fold), or L452R (5.8-fold) substitutions. Variants with reduced susceptibility to tixagevimab alone included those with Q414R (4.6-fold), L455F (2.5- to 4.7-fold), G476S (3.3-fold), E484D (7.1-fold), G476V (121- to 149-fold), Q493K (2.4- to 3.2-fold), Q493R (7.9-fold), and E990A (6.1-fold), or T1009I (8.2-fold) substitutions. Variants harboring an E484K (2.4- to 5.4-fold), Q493R (3.4-fold), E990A (5.7-fold), or T1009I (4.5-fold) substitution exhibited low level reduced susceptibility to tixagevimab and cilgavimab in combination.

VLPs pseudotyped with the SARS-CoV-2 spike of variant strains with reduced susceptibility to cilgavimab included those with R346K:E484K:N501Y (Mu, 21-fold), and those with reduced susceptibility to tixagevimab included those harboring E484K (Alpha, 18.5-fold; Beta, 3.5- to 15-fold). Similar results were observed, where data was available, in neutralization assays using authentic SARS-CoV-2 variant strains.

Tixagevimab and cilgavimab in combination retained neutralization activity against pseudotyped VLPs and/or authentic SARS-CoV-2 variant strains harboring all spike substitutions identified in Alpha (B.1.1.7, 0.5- to 5.2-fold), Beta (B.1.351, 1.0- to 3.8-fold), Gamma (P.1, 0.4- to 2.0-fold) and Delta (B.1.617.2, 0.6- to 1.2-fold) variants of concern, and Eta (B.1.525, 3.1-fold), Iota (B.1.526, 0.3- to 3.4-fold), Kappa (B.1.617.1, 0.5- to 3.4-fold) Lambda (C.37, 0.7-fold), and Mu (B.1.621, 7.5-fold) variants of interest. Tixagevimab and cilgavimab in combination also retained neutralization activity against Epsilon (B.1.427 / B.1.429, 0.8- to 3.5-fold), R.1 (3.5-fold), B.1.1.519 (1.4-fold), C.36.3 (2.3-fold), B.1.214.2 (0.8-fold), and B.1.619.1 (3.3-fold) variant alerts for further monitoring and B.1.616 (0.5-fold), A.23.1 (0.4-fold), A.27 (0.8-fold), and AV.1 (5.9-fold) variants de-escalated from further monitoring (Table 5).

Table 5 Pseudotyped Virus-Like Particles and Authentic SARS-CoV-2 Neutralization Data for SARS-CoV-2 Variant Substitutions with EVUSHELD

<table>
<thead>
<tr>
<th>Lineage with Spike</th>
<th>Country First</th>
<th>WHO Nomenclature</th>
<th>Key Substitutions Tested</th>
<th>Fold Reduction in</th>
<th>Fold Reduction in</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Protein Substitution</td>
<td>Identified</td>
<td>Identified Substitutions</td>
<td>Susceptibility (Pseudotyped VLPs)</td>
<td>Susceptibility (Authentic virus)</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------</td>
<td>--------------------------</td>
<td>-----------------------------------</td>
<td>----------------------------------</td>
<td></td>
</tr>
<tr>
<td>B.1.1.7</td>
<td>UK</td>
<td>Alpha</td>
<td>N501Y</td>
<td>0.5- to 5.2-fold</td>
<td>No Change§</td>
</tr>
<tr>
<td>B.1.351</td>
<td>South Africa</td>
<td>Beta</td>
<td>K417N+E484K+N501Y</td>
<td>No Change§</td>
<td>No Change§</td>
</tr>
<tr>
<td>P.1</td>
<td>Brazil</td>
<td>Gamma</td>
<td>K417T+E484K+N501Y</td>
<td>No Change§</td>
<td>No Change§</td>
</tr>
<tr>
<td>B.1.617.2</td>
<td>India</td>
<td>Delta</td>
<td>L452R+T478K</td>
<td>No Change§</td>
<td>No Change§</td>
</tr>
<tr>
<td>AY.1/AY.2</td>
<td>India</td>
<td>Delta [+K417N]</td>
<td>K417N+L452R+T478K</td>
<td>No Change§</td>
<td>No Change§</td>
</tr>
<tr>
<td>B.1.525</td>
<td>Multiple country origin</td>
<td>Eta</td>
<td>E484K</td>
<td>No Change§</td>
<td>ND</td>
</tr>
<tr>
<td>B.1.526</td>
<td>United States</td>
<td>Iota</td>
<td>E484K</td>
<td>No Change§</td>
<td>No Change§</td>
</tr>
<tr>
<td>B.1.617.1</td>
<td>India</td>
<td>Kappa</td>
<td>L452R+E484Q</td>
<td>No Change§</td>
<td>No Change§</td>
</tr>
<tr>
<td>C.37</td>
<td>Peru</td>
<td>Lambda</td>
<td>L452Q+F490S</td>
<td>No Change§</td>
<td>ND</td>
</tr>
<tr>
<td>B.1.621</td>
<td>Columbia</td>
<td>Mu</td>
<td>R346K+E484K+N501Y</td>
<td>7.5-fold</td>
<td>ND</td>
</tr>
<tr>
<td>B.1.427 / B.1.429</td>
<td>United States</td>
<td>Epsilon</td>
<td>L452R</td>
<td>No Change§</td>
<td>No Change§</td>
</tr>
<tr>
<td>R.1</td>
<td>Multiple country origin</td>
<td>-</td>
<td>E484K</td>
<td>No Change§</td>
<td>ND</td>
</tr>
<tr>
<td>B.1.1.519</td>
<td>Multiple country origin</td>
<td>-</td>
<td>T478K</td>
<td>No Change§</td>
<td>ND</td>
</tr>
<tr>
<td>B.1.616</td>
<td>France</td>
<td>-</td>
<td>V483A</td>
<td>No Change§</td>
<td>ND</td>
</tr>
<tr>
<td>A.23.1</td>
<td>UK</td>
<td>-</td>
<td>V367F</td>
<td>No Change§</td>
<td>ND</td>
</tr>
<tr>
<td>A.27</td>
<td>Multiple country origin</td>
<td>-</td>
<td>L452R+N501Y</td>
<td>No Change§</td>
<td>ND</td>
</tr>
</tbody>
</table>
ND, not determined; RBD, receptor binding domain

* Range of reduced potency across multiple variants of each lineage using research-grade pseudotyped VLP neutralization assays; mean fold change in half maximal inhibitory concentration (EC\textsubscript{50}) of mAb required for a 50% reduction in infection compared to wild type reference strain
† Pseudotyped virus-like particles expressing the entire SARS-CoV-2 spike variant protein and individual characteristic spike substitutions except L452Q were tested including Alpha (+L455F, E484K, F490S, Q493R, and/or S494P), and Delta (+K417N) harboring additional indicated RBD substitutions that are no longer detected or detected at extremely low levels within these lineages
‡ Authentic SARS-CoV-2 expressing the entire variant spike protein were tested including Alpha (+E484K or S494P) harboring additional indicated RBD substitutions that are no longer detected or detected at extremely low levels within these lineages
§ No change: <5-fold reduction in susceptibility

It is not known how pseudotyped VLPS or authentic SARS-CoV-2 neutralization susceptibility data correlate with clinical outcome.

In PROVENT, illness visit sequencing data were available for 21 of 33 subjects with SARS-CoV-2 infection (6 of 13 who received tixagevimab and cilgavimab and 15 of 20 placebo). At an allele fraction ≥25%, 14 of 21 subjects were infected with variants of concern or variants of interest, including 8 subjects with Alpha (B.1.1.7) (8 who received placebo), 1 subject with Beta (B.1.351) (1 who received tixagevimab and cilgavimab), 3 subjects with Delta (B.1.617.2) (3 who received placebo), and 2 subjects with Epsilon (B.1.429) (2 who received tixagevimab and cilgavimab). Seven additional subjects were infected with B.1.375 (1 who received tixagevimab and cilgavimab) or the A_1 set of lineages containing a constellation of spike protein substitutions including D614G and P681H or Q677P (3 who received tixagevimab and cilgavimab and 3 placebo). Additional spike protein RBD substitutions detected at an allele fraction ≥3% included V503F in the tixagevimab and cilgavimab group.

In STORM CHASER, illness visit sequencing data was available for 19 subjects with SARS-CoV-2 infections (12 of 12 who received tixagevimab and cilgavimab and 7 of 7 placebo). At an allele fraction ≥25%, 12 of 19 subjects were infected with variants of concern or variants of interest, including 9 subjects with Alpha (B.1.1.7) (5 who received tixagevimab and cilgavimab and 4 placebo) and 3 subjects with Epsilon (B.1.427 / B.1.429) (2 who received tixagevimab and cilgavimab and 1 placebo). Seven additional subjects were infected with B.1.1.519 (1 who received tixagevimab and cilgavimab) or the A_1 set of lineages containing a constellation of spike protein substitutions including D614G and D138H, Q675H, Q677H, or V1176F (4 who received tixagevimab and cilgavimab and 2 placebo). Additional spike protein RBD substitutions detected at an allele fraction ≥3% included S325P, Del342, C361W, Del428, F429V, and F515C in the tixagevimab and cilgavimab group.

Evaluation of neutralization susceptibility of variants identified through global surveillance and in subjects who received tixagevimab and cilgavimab is ongoing.

It is possible that variants resistant to tixagevimab and cilgavimab could have cross-resistance to other monoclonal antibodies targeting the RBD of SARS-CoV-2. The combination of tixagevimab and cilgavimab retained activity against pseudotyped VLPS harboring individual SARS-CoV-2 spike substitutions (K417E/N, D420N, K444Q, V445A, Y453F, L455F, N460K/S/T, E484D/K/Q, F486V, F490S, Q493K/R, and S494P) identified in neutralization escape variants of other monoclonal antibodies targeting the RBD of SARS-CoV-2 spike protein.

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, genotoxicity, and reproductive toxicology studies have not been conducted with tixagevimab and cilgavimab.

13.2 Animal Toxicology and Pharmacology

In a toxicology study in cynomolgus monkeys, tixagevimab and cilgavimab had no adverse effects when administered via IM injection.

In tissue cross-reactivity studies with tixagevimab and cilgavimab using human adult and fetal tissues no binding of clinical concern was detected.

Tixagevimab and cilgavimab have been assessed in rhesus macaque and cynomolgus macaque models of SARS-CoV-2 infection. Prophylactic administration of tixagevimab and cilgavimab (N= 4 rhesus macaque; N= 3 cynomolgus macaque) three days prior to infection prevented SARS-CoV-2 infection of the upper and lower respiratory tracts in dose-dependent manner. Prophylactic administration of 4 mg/kg tixagevimab and cilgavimab resulted in a 7-log10 reduction in viral sub-genomic messenger RNA (sgmRNA) in nasopharyngeal swabs and 5 to 6-log10 reduction in sgmRNA or infectious virus titer in bronchoalveolar lavage samples at Day 2 post-challenge in all animals relative to placebo-treated animals.

Compared to placebo, prophylactic administration of tixagevimab and cilgavimab (N= 3 cynomolgus macaque) reduced lung injury associated with SARS-CoV-2 infection.

The applicability of these findings to a clinical setting is not known.

14 CLINICAL STUDIES

The data supporting this EUA are based on analyses from the Phase III trials PROVENT (NCT04625725) and STORM CHASER (NCT04625972). Both trials are evaluating the safety and efficacy of EVUSHELD (150 mg of tixagevimab and 150 mg of cilgavimab) for the prophylaxis SARS-CoV-2 symptomatic illness (COVID-19).

Efficacy Data from PROVENT

PROVENT is an ongoing Phase III, randomized (2:1), double-blind, placebo-controlled clinical trial studying EVUSHELD for the pre-exposure prophylaxis of COVID-19 in adults ≥18 years of age. All subjects were either ≥60 years of age, had a pre-specified co-morbidity (obesity, congestive heart failure, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, immunocompromised state, or previous history of severe or serious adverse event after receiving any approved vaccine), or were at increased risk of SARS-CoV-2 infection due to their living situation or occupation. Subjects could not have previously received a COVID-19 vaccine. Subjects received a single dose (administered as two IM injections) of EVUSHELD or placebo. The study excluded subjects with a history of laboratory-confirmed SARS-CoV-2 infection or SARS-CoV-2 antibody positivity at screening. Once COVID-19 vaccines were locally available, subjects were permitted on request to unblind to make an informed decision on vaccine timing and to receive COVID-19 vaccination.

The baseline demographics were balanced across the EVUSHELD and placebo arms. The median age was 57 years (with 43% of subjects aged 60 years or older), 46% of subjects were female, 73% were White, 3% were Asian 17% were Black/African American, and 15% were Hispanic/Latino. Of the 5,197 subjects, 78% had baseline co-morbidities or characteristics associated with an increased risk for severe COVID-19, including obesity (42%), diabetes (14%), cardiovascular disease (8%), cancer, including a history of cancer (7%), chronic obstructive pulmonary disease (5%), chronic kidney
For the primary endpoint, a subject was defined as a COVID-19 case if their first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurred after administration and prior to Day 183. The primary analysis included 5,172 subjects who were SARS-CoV-2 RT-PCR-negative at baseline, of which 3,441 received EVUSHELD and 1,731 received placebo. Only events that occurred prior to unblinding or vaccine receipt were included. EVUSHELD receipt resulted in a statistically significant (p-value <0.001) 77% reduction in incidence of SARS-CoV-2 RT-PCR-positive symptomatic illness (COVID-19) when compared to placebo (Table 6). At the time of analysis the median follow-up time post-administration was 83 days (range 3 to 166 days).

Similar results were observed for EVUSHELD recipients compared to placebo recipients in the reduction in incidence of SARS-CoV-2 RT-PCR-positive symptomatic illness or death from any cause (12/3,441 versus 19/1,731, respectively) with relative risk reduction of 69% (95% CI: 36, 85; p-value= 0.002), and in the reduction in incidence of SARS-CoV-2 RT-PCR-positive symptomatic illness regardless of unblinding or vaccine receipt (10/3,441 versus 22/1,731, respectively) with relative risk reduction of 77% (95% CI: 52, 89 ; p-value <0.001).

**Table 6 Incidence of Symptomatic COVID-19 in Adults (PROVENT)**

<table>
<thead>
<tr>
<th></th>
<th>N</th>
<th>Number of events, n (%)</th>
<th>Relative Risk Reduction, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EVUSHELD†</td>
<td>3,441</td>
<td>8 (0.2%)</td>
<td>77% (46, 90)</td>
</tr>
<tr>
<td>Placebo</td>
<td>1,731</td>
<td>17 (1.0%)</td>
<td></td>
</tr>
</tbody>
</table>

N = number of subjects in analysis; CI = Confidence Interval
* subjects were censored after receiving the vaccine or being unblinded to consider the vaccine, whichever occurred earlier
† EVUSHELD dose (150 mg tixagevimab and 150 mg cilgavimab)

Among subjects who received EVUSHELD, there were no severe/critical COVID-19 events (defined as SARS-CoV-2 RT-PCR-positive symptomatic illness characterized by a minimum of either pneumonia [fever, cough, tachypnoea or dyspnea, and lung infiltrates] or hypoxemia [SpO2 <90% in room air and/or severe respiratory distress] and a WHO Clinical Progression Scale score of 5 or higher) compared to one event (0.1%) among subjects who received placebo.

An additional data cut was conducted to provide post-hoc updated efficacy and safety analysis, the median follow-up was 6.5 months for subjects in both EVUSHELD and placebo arms. The relative risk reduction of SARS-CoV-2 RT-PCR-positive symptomatic illness was 83% (95% CI: 66, 91) with 11/3,441 (0.3%) events in the EVUSHELD arm and 31/1,731 (1.8%) events in the placebo arm, see Figure 1. These results are consistent with the duration of protection predicted by population PK modelling [see Clinical Pharmacology (12.3)]. Among subjects who received EVUSHELD there were no severe/critical COVID-19 events compared to five events among subjects who received placebo.
Efficacy Data from STORM CHASER

STORM CHASER is an ongoing Phase III randomized (2:1), double-blind, placebo-controlled clinical trial of EVUSHELD for the post-exposure prophylaxis of COVID-19 in adults ≥18 years of age. Subjects who had not previously received a COVID-19 vaccine were enrolled following potential exposure (within 8 days) to an identified individual with a laboratory-confirmed SARS-CoV-2 infection (symptomatic or asymptomatic). Subjects received a single dose (administered as two IM injections) of EVUSHELD or placebo. The study excluded subjects with a history of laboratory-confirmed SARS-CoV-2 infection or SARS-CoV-2 antibody positivity at screening. Once COVID-19 vaccines were locally available, subjects were permitted on request to unblind to make an informed decision on vaccine timing and to receive COVID-19 vaccination.

Of the 1,121 subjects who were randomized and received EVUSHELD (N= 749) or placebo (N= 372), 48 subjects were positive for SARS-CoV-2 (RT-PCR analysis of nasopharyngeal swabs) at baseline.

The primary efficacy analysis, comparison of the incidence of a subject's first case of SARS-CoV-2 RT-PCR-positive symptomatic illness occurring post-dose and before Day 183, did not demonstrate a statistically significant effect for EVUSHELD versus placebo with 23 cases of symptomatic COVID-19 in the EVUSHELD arm (3.1%) and 17 cases in the placebo arm (4.6%) (relative risk reduction of 33%, 95% CI: -26, 65). At the time of analysis the median follow-up time post-administration was 49 days (range 5 to 115 days).

The study did not demonstrate benefit for EVUSHELD in preventing symptomatic COVID-19 in the first 30 days after randomization, leading to the limitation of use for post-exposure prophylaxis [see Emergency Use Authorization (1)]. However, there was a higher proportion of symptomatic COVID-19 cases among placebo recipients after Day 29 (see Figure 2 below, data from the post-hoc updated efficacy analysis with a median follow-up time of 6.5 months). EVUSHELD is not authorized for post-exposure
prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2.

![Figure 2 Kaplan Meier: Cumulative Incidence of Symptomatic COVID-19* (STORM CHASER)](image)

* Subjects who do not experience a primary endpoint event (and had not discontinued) are censored at Day 183.

16 HOW SUPPLIED/STORAGE AND HANDLING

How Supplied

Each EVUSHELD co-packaged carton contains two vials (Table 7):

- 1 single-dose vial of tixagevimab injection as a sterile, preservative-free, clear to opalescent and colorless to slightly yellow solution.
- 1 single-dose vial of cilgavimab injection as a sterile, preservative-free, clear to opalescent and colorless to slightly yellow solution.

<table>
<thead>
<tr>
<th>Carton (2 vials per pack)</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1 vial of Tixagevimab 150 mg/1.5 mL (100 mg/mL) (dark grey cap)</td>
</tr>
<tr>
<td>NDC 0310-7442-02</td>
<td>NDC 0310-8895-01</td>
</tr>
</tbody>
</table>

Storage and Handling

Store unopened vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Discard any unused portion.
17 PATIENT COUNSELING INFORMATION

As a prescribing healthcare practitioner, you must communicate to the patient, parent and caregiver information consistent with the “FACT SHEET FOR PATIENTS, PARENTS OR CAREGIVERS” and provide them with a copy of this Fact Sheet prior to administration of EVUSHELD.

Cardiovascular Events
Inform individuals that a higher proportion of subjects who received EVUSHELD versus placebo reported cardiovascular serious adverse events (myocardial infarctions and heart failure). Advise individuals to seek immediate medical attention if they experience any signs or symptoms suggestive of a cardiovascular event [see Warnings and Precautions (5.3)].

For additional information, please visit the website or call the telephone number provided below.

To access the most recent EVUSHELD Fact Sheets, please scan the QR code provided below.

<table>
<thead>
<tr>
<th>Website</th>
<th>Telephone number</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://www.evusheld.com">http://www.evusheld.com</a></td>
<td>1-800-236-9933</td>
</tr>
</tbody>
</table>

18 MANUFACTURER INFORMATION

Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850

Manufactured by: Samsung Biologics, 300 Songdo Bio-daero, Yeonsu-gu, Incheon 21987,
Republic of Korea
with cilgavimab) for Coronavirus Disease 2019 (COVID-19)

You are being given this Fact Sheet because your healthcare provider believes it is necessary to provide you with EVUSHELD (tixagevimab co-packaged with cilgavimab) for pre-exposure prophylaxis for prevention of coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus.

This Fact Sheet contains information to help you understand the potential risks and potential benefits of taking EVUSHELD, which you have received or may receive.

The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) to make EVUSHELD available during the COVID-19 pandemic (for more details about an EUA please see “What is an Emergency Use Authorization?” at the end of this document). EVUSHELD is not an FDA-approved medicine in the United States.

Read this Fact Sheet for information about EVUSHELD. Talk to your healthcare provider if you have any questions. It is your choice to receive or not receive EVUSHELD.

What is COVID-19?

COVID-19 is caused by a virus called a coronavirus. You can get COVID-19 through close contact with another person who has the virus.

COVID-19 illnesses have ranged from very mild (including some with no reported symptoms) to severe, including illness resulting in death. While information so far suggests that most COVID-19 illness is mild, serious illness can happen and may cause some of your other medical conditions to become worse. Older people and people of all ages with severe, long-lasting (chronic) medical conditions like heart disease, lung disease, and diabetes, for example, seem to be at higher risk of being hospitalized for COVID-19.

What is EVUSHELD (tixagevimab co-packaged with cilgavimab)?

EVUSHELD is an investigational medicine used in adults and adolescents (12 years of age and older who weigh at least 88 pounds [40 kg]) for pre-exposure prophylaxis for prevention of COVID-19 in persons who are:

- not currently infected with SARS-CoV-2 and who have not had recent known close contact with someone who is infected with SARS-CoV-2 and
  - Who have moderate to severe immune compromise due to a medical condition or have received immunosuppressive medicines or treatments and may not mount an adequate immune response to COVID-19 vaccination or
  - For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (such as severe allergic reaction) to a COVID-19 vaccine(s) or COVID-19 vaccine ingredient(s).

EVUSHELD is investigational because it is still being studied. There is limited information known about the safety and effectiveness of using EVUSHELD for pre-exposure prophylaxis for prevention of COVID-19. EVUSHELD is not authorized for post-exposure prophylaxis for prevention of COVID-19.

The FDA has authorized the emergency use of EVUSHELD for pre-exposure prophylaxis for prevention of COVID-19 under an Emergency Use Authorization (EUA).

What should I tell my healthcare provider before I receive EVUSHELD?

Tell your healthcare provider if you:

- Have any allergies
• Have low numbers of blood platelets (which help blood clotting), a bleeding disorder, or are taking anticoagulants (to prevent blood clots)
• Have had a heart attack or stroke, have other heart problems, or are at high-risk of cardiac (heart) events
• Are pregnant or plan to become pregnant
• Are breastfeeding a child
• Have any serious illness
• Are taking any medications (prescription, over-the-counter, vitamins, or herbal products)

**How will I receive EVUSHELD?**

• EVUSHELD consists of two investigational medicines, tixagevimab and cilgavimab.
• You will receive 1 dose of EVUSHELD, consisting of 2 separate injections (tixagevimab and cilgavimab).
• EVUSHELD will be given to you by your healthcare provider as 2 intramuscular injections. They are usually, given one after the other, 1 into each of your buttocks.

After the initial dose, if your healthcare provider determines that you need to receive additional doses of EVUSHELD for ongoing protection, the additional doses would be administered once every 6 months.

**Who should generally not take EVUSHELD?**

Do not take EVUSHELD if you have had a severe allergic reaction to EVUSHELD or any ingredient in EVUSHELD.

**What are the important possible side effects of EVUSHELD?**

Possible side effects of EVUSHELD are:

• **Allergic reactions.** Allergic reactions can happen during and after injection of EVUSHELD. Tell your healthcare provider right away if you get any of the following signs and symptoms of allergic reactions: fever, chills, nausea, headache, shortness of breath, low or high blood pressure, rapid or slow heart rate, chest discomfort or pain, weakness, confusion, feeling tired, wheezing, swelling of your lips, face, or throat, rash including hives, itching, muscle aches, dizziness and sweating. These reactions may be severe or life threatening.

• **Cardiac (heart) events:** Serious cardiac adverse events have happened, but were not common, in people who received EVUSHELD and also in people who did not receive EVUSHELD in the clinical trial studying pre-exposure prophylaxis for prevention of COVID-19. In people with risk factors for cardiac events (including a history of heart attack), more people who received EVUSHELD experienced serious cardiac events than people who did not receive EVUSHELD. It is not known if these events are related to EVUSHELD or underlying medical conditions. Contact your healthcare provider or get medical help right away if you get any symptoms of cardiac events, including pain, pressure, or discomfort in the chest, arms, neck, back, stomach or jaw, as well as shortness of breath, feeling tired or weak (fatigue), feeling sick (nausea), or swelling in your ankles or lower legs.

The side effects of getting any medicine by intramuscular injection may include pain, bruising of the skin, soreness, swelling, and possible bleeding or infection at the injection site.

These are not all the possible side effects of EVUSHELD. Not a lot of people have been given EVUSHELD. Serious and unexpected side effects may happen. EVUSHELD is still being studied so it is possible that all of the risks are not known at this time.

It is possible that EVUSHELD may reduce your body’s immune response to a COVID-19
vaccine. If you have received a COVID-19 vaccine, you should wait to receive EVUSHELD until at least 2 weeks after COVID-19 vaccination.

**What other prevention choices are there?**


It is your choice to receive or not receive EVUSHELD. Should you decide not to receive EVUSHELD, it will not change your standard medical care. EVUSHELD is not authorized for post-exposure prophylaxis of COVID-19.

**What if I am pregnant or breastfeeding?**

If you are pregnant or breastfeeding, discuss your options and specific situation with your healthcare provider.

**How do I report side effects with EVUSHELD?**

Contact your healthcare provider if you have any side effects that bother you or do not go away. Report side effects to FDA MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088 or call AstraZeneca at 1-800-236-9933.

**Additional Information**

If you have questions, visit the website or call the telephone number provided below.

To access the most recent EVUSHELD Fact Sheets, please scan the QR code provided below.

<table>
<thead>
<tr>
<th>Website</th>
<th>Telephone number</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="http://www.evusheld.com">http://www.evusheld.com</a></td>
<td>1-800-236-9933</td>
</tr>
</tbody>
</table>

**How can I learn more about COVID-19?**

- Ask your healthcare provider.
- Visit https://www.cdc.gov/COVID19
- Contact your local or state public health department.

**What is an Emergency Use Authorization?**

The United States FDA has made EVUSHELD (tixagevimab co-packaged with cilgavimab) available under an emergency access mechanism called an Emergency Use Authorization EUA. The EUA is supported by a Secretary of Health and Human Service (HHS) declaration that circumstances exist to justify the emergency use of drugs and biological products during the COVID-19 pandemic.

(COVID-19) caused by the SARS-CoV-2 virus has not undergone the same type of review as an FDA-approved product. In issuing an EUA under the COVID-19 public health emergency, the FDA has determined, among other things, that based on the total amount of scientific evidence available including data from adequate and well-controlled clinical trials, if available, it is reasonable to believe that the product may be effective for diagnosing, treating, or preventing COVID-19, or a serious or life-threatening disease or condition caused by COVID-19; that the known and potential benefits of the product, when used to diagnose, treat, or prevent such disease or condition, outweigh the known and potential risks of such product; and that there are no adequate, approved and available alternatives.

All of these criteria must be met to allow for the product to be used in the treatment of patients during the COVID-19 pandemic. The EUA for EVUSHELD is in effect for the duration of the COVID-19 declaration justifying emergency use of EVUSHELD, unless terminated or revoked (after which EVUSHELD may no longer be used under the EUA).

Distributed by: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850
Manufactured by: Samsung Biologics, 300 Songdo bio-daero, Yeonsu-gu, Incheon 21987, Republic of Korea
©AstraZeneca 2021. All rights reserved.

Package/Label Display Panel
tixagevimab
Injection
150 mg/1.5 mL
(100mg/mL)
For Intramuscular Use.
1.5 mL single-dose vial.
MUST ADMINISTER WITH CILGAVIMAB
Rx only
NDC 0310-8895-01
Discard unused portion.
No preservative. Store at 2° to 8°C (36° to 46°F).
Do not freeze or shake.
Protect from light.
For use under Emergency Use Authorization (EUA)
AstraZeneca

Package/Label Display Panel
cilgavimab
Injection
150 mg/1.5 mL
(100mg/mL)
For Intramuscular Use.
1.5 mL single-dose vial.
MUST ADMINISTER WITH TIXAGEVIMAB
Rx only
NDC 0310-1061-01
Discard unused portion.
No preservative. Store at 2° to 8°C (36° to 46°F).
Do not freeze or shake.
Protect from light.
For use under Emergency Use Authorization (EUA)
AstraZeneca
Package/Label Display Panel
NDC 0310-7442-02

EVUSHIELD™
(tixagevimab) Injection
150 mg/1.5 mL
(100mg/mL)
Co-packaged with
(cilgavimab) injection
150 mg/1.5 mL
(100mg/mL)

For use under Emergency Use Authorization (EUA)
For Intramuscular Use
Keep vials in original carton to protect from light.

Discard unused portion.

Each carton contains two (2) vials:
One 1.5 mL single-dose vial of tixagevimab
One 1.5 mL single-dose vial of cilgavimab

ATTENTION HEALTHCARE PROVIDER: EACH VIAL MUST BE ADMINISTERED SEPARATELY BY INTRAMUSCULAR INJECTION
Refer to FDA-Authorized Fact Sheets for Dosage and Administration.
Rx only AstraZeneca
EVUSHELD
azd7442 kit

Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>Item Code (Source)</th>
<th>NDC:0310-7442</th>
</tr>
</thead>
</table>

Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0310-7442-02</td>
<td>1 in 1 PACKAGE; Type 0: Not a Combination Product</td>
</tr>
</tbody>
</table>

Quantity of Parts

<table>
<thead>
<tr>
<th>Part #</th>
<th>Package Quantity</th>
<th>Total Product Quantity</th>
</tr>
</thead>
</table>
### Part 1

**AZD1061**

azd1061 injection, solution

### Product Information

<table>
<thead>
<tr>
<th>Item Code (Source)</th>
<th>NDC:0310-1061</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>INTRAVENOUS, INTRAMUSCULAR</td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>CILGAVIMAB (UNII: 1KUR4BN70F) (CILGAVIMAB - UNII:1KUR4BN70F)</td>
<td>CILGAVIMAB</td>
<td>150 mg in 1.5 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>HISTIDINE (UNII: 4QD397987E)</td>
<td>2.4 mg in 1.5 mL</td>
</tr>
<tr>
<td>HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE (UNII: X573657P6P)</td>
<td>3.0 mg in 1.5 mL</td>
</tr>
<tr>
<td>SUCROSE (UNII: C151H8M554)</td>
<td>123.2 mg in 1.5 mL</td>
</tr>
<tr>
<td>POLYSORBATE 80 (UNII: 60ZP39ZG8H)</td>
<td>0.6 mg in 1.5 mL</td>
</tr>
<tr>
<td>WATER (UNII: 059QF0KOOR)</td>
<td>1312 mg in 1.5 mL</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0310-1061-01</td>
<td>1.5 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Use Authorization</td>
<td></td>
<td>12/08/2021</td>
<td></td>
</tr>
</tbody>
</table>

### Part 2

**AZD8895**

azd8895 injection, solution

### Product Information

| Item Code (Source) | NDC:0310-8895 |
### Route of Administration
INTRAVENOUS, INTRAMUSCULAR

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIXAGEVIMAB</td>
<td>TIXAGEVIMAB</td>
<td>150 mg in 1.5 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>HISTIDINE</td>
<td>2.4 mg in 1.5 mL</td>
</tr>
<tr>
<td>HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE</td>
<td>3.0 mg in 1.5 mL</td>
</tr>
<tr>
<td>SUCROSE</td>
<td>123.2 mg in 1.5 mL</td>
</tr>
<tr>
<td>POLYSORBATE 80</td>
<td>0.6 mg in 1.5 mL</td>
</tr>
<tr>
<td>WATER</td>
<td>1312 mg in 1.5 mL</td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0310-8895-01</td>
<td>1.5 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emergency Use Authorization</td>
<td></td>
<td>12/08/2021</td>
<td></td>
</tr>
</tbody>
</table>

### Labeler
AstraZeneca Pharmaceuticals LP (054743190)

### Registrant
AstraZeneca PLC (230790719)

Revised: 12/2021